Upcoming Events

  1. World Drug Safety Congress Americas 2018

    April 10, 2018 - April 11, 2018

Register Today!

Get Free Test Access

2013 Year in review: Clinical Development[:de]2013 Year in review: Clinical Development

  • Average clinical trials Submissions in 2013: Phase I – 314 studies per Quartile, phase II – 233 studies per Quartile, Phase III – 237 studies per Quartile;
  • R&D Spending in Pharma goes down by 5% in 2013 and in Generics jumps by 18%:
  • Major partnership: Wuintils and Merk Serono
  • Major M&As made by: Quintiles, PPD, JLL; KKR
  • Top 5 CROs accoutn for 50% of the total market and top 8 CRO account for 66% of the market.

23-01-2014 11-01-15

23-01-2014 11-01-03

More here: http://goo.gl/2kB9Vw
And Pharma Core industry Metrics: http://goo.gl/6CvhOy

[:de]
  • Average clinical trials Submissions in 2013: Phase I – 314 studies per Quartile, phase II – 233 studies per Quartile, Phase III – 237 studies per Quartile;
  • R&D Spending in Pharma goes down by 5% in 2013 and in Generics jumps by 18%:
  • Major partnership: Wuintils and Merk Serono
  • Major M&As made by: Quintiles, PPD, JLL; KKR
  • Top 5 CROs accoutn for 50% of the total market and top 8 CRO account for 66% of the market.

23-01-2014 11-01-15

23-01-2014 11-01-03

More here: http://goo.gl/2kB9Vw
And Pharma Core industry Metrics: http://goo.gl/6CvhOy

By | 2016-11-16T18:35:48+00:00 December 23, 2013|News|Comments Off on 2013 Year in review: Clinical Development[:de]2013 Year in review: Clinical Development

About the Author:

Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.